Compugen Ltd.

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's second quarter 2026 results conference call. At this time, all participants are in list and only mode. An audio webcast of this call is available in the investor section of Compugen's website at www.cgen.com. As a reminder, today's call is being recorded. I will now hand the call over to Lindsay Trickett, Head of Investor Relations and Corporate Communications to begin. Lindsay, please go ahead.

Thank you, Operator. Good morning and good afternoon, everyone, and welcome to CONFIGEN's second quarter 2026 Financial Results Conference Call. With us today are Dr. Eran Ophir, President and Chief Executive Officer, and David Silberman, Chief Financial Officer. Dr. Michelle Mahler, Chief Medical Officer, will join us for the Q&A portion of the call. Before we begin, I'd like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts, and their potential outcomes. The company's discovery platform, anticipated progress and plans, results and timelines for our programs, including disclosure of clinical data, financial and accounting-related matters, as well as statements regarding our cash position and cash runway. We wish to caution you that such statements reflect only the company's current beliefs, expectations, and assumptions, and that actual results, performance, or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties, and we refer you to our SEC filings for more details on these risks, including the company's most recent annual report on Form 20-F. The company undertakes no obligation to update projections and forward-looking statements in the future. With that, I'll now turn the call over to Eran.

Thank you, Lindsay, and good morning, everyone. Q2 was a quarter of steady advancement, and I am pleased with the progress they have made across every part of the company. Our science continues to advance in the clinic, and our partnerships are advancing on strong footing. Our myovarant trial in platinum-sensitive ovarian cancer is progressing as in on track for the interim analysis by Q1 2027. We were encouraged to see AstraZeneca continue to build momentum behind rilvogostomib by initiating a new phase three trial in urothelial carcinoma and with new data at ASCO from the Gemini study in hepatobiliary cancer and the investigator-initiated i-SPI trial in breast cancer. Lastly, our collaboration with Gilead on GS0321 continued to progress as planned And underpinning all of this is the same disciplined, data-driven approach that has always defined COMPOGEN. Now let me take each program one by one, starting with our only home program, COM701, a potential first-class antipyvergy antibody. We continue to make good progress with myOvarian, our sponsored randomized placebo-controlled adaptive platform trial, evaluating COM701, its maintenance monotherapy, in patients with second- and third-line relapsed platinum-sensitive ovarian cancer in a setting with no approved maintenance treatment option and significant unmet needs. We anticipate interim analysis with median progression-free survival data by the first quarter of 2027. During this quarter, we were pleased to present a trial-in-progress poster on myovarian at the Esmogen Ecological Cancers Congress in Copenhagen. The poster underscored the strong biological and clinical rationale for evaluating COM7-1 in this population, including the differentiated biology of the PBRG pathway versus other checkpoints like PD-1 and digits, its high expression in ovarian cancer, and the durable responses previously observed with COM7-1 in mono and combination therapy in heavily pretreated platinum-resistant patients. As we prepare for the myovarian interim analysis, we have been keeping close tabs on the emerging external data to keep our own expectations anchored in the current clinical context. Two recent clinical trials in relapsed platinum-sensitive ovarian cancer, that include in patients who have been pre-treated with spalpinibutols or bevacizumab or both, have shown median progression-free survival for the control arm of less than three months. While the patient population of these two trials is not identical and more heavily protruded than the Maya trial population, based on these data, we estimate the median PSS of the placebo control group in our trial to be approximately four months. As a reminder, patients with ovarian cancer are divided into either platinum sensitive or platinum resistant categories, with the difference being the duration of their platinum free interval. If a patient relapses in less than six months following platinum-based chemotherapy, they move into platinum-resistant category, where further platinum therapy is generally no longer considered effective and treatment shifts to non-platinum options. For the interim analysis, we define clinically meaningful success as COM701 helping patients remain progression-free for at least six months after platinum-based chemotherapy. Achieving these thresholds maintains patients as platinum-sensitive for longer, delays their transition to platinum-resistant disease, and gives patients a valuable recovery break for the intensity of chemotherapy, thereby improving quality of life while preserving additional treatment options and potentially changing their disease course. Overall, we believe COM701's anti-tumor activity will be best assessed by the totality of the data comparing the treatment effects against our blinded randomized control arm. MYA is an exploratory trial designed to evaluate COM7-1 monotherapy and the magnitude of its effects. It is not a registration trial powered to demonstrate a statistical difference between the treatment groups. Nevertheless, we believe that comparing COM7-1 as a monotherapy against a placebo control We allow us to draw clear conclusions about the clinical activity. Looking ahead, we believe that clear prolongation of PFS in these patients could inform a registration path for COM701 and establish it as a potential backbone for drug combinations in this population, while also enabling a potential broader clinical development plan across earlier and later lines of ovarian cancer treatment, as well as in other indications where clinical signals were previously seen for COM701. Turning to Rivagostamine, the PD-1-tigit bispecific antibody being advanced by our partner, AstraZeneca, the tigit component of which is derived from our fully-owned COM902 program. In the last week, AZ has added a 12-phase free trial to the overall real vet program in participants with high-risk muscle-invasive urothelial carcinoma. In this trial, will be combined with DAPRO-A, their approved TROP2 ADC, and tested in adjuvant settings against TANATOF-KER. This new phase three trial, Tropion-Ureterial O4, follows the phase two Tropion-Pentumal O3 study in which RILVE plus DATOCOMBO showed an encouraging efficacy and a manageable safety profile in a metastatic ureterial carcinoma. We also encouraged but the addition of RILVE data AstraZeneca presented at 2026 ASCO Annual Meeting which we believe continues to support the differentiated profile of this bispecific and its potential as an immuno-oncology backbone across multiple tumor types. In advanced biliary tract cancer, AstraZeneca presented an updated analysis from the Gemini Hepatovolibularis study of RILVE in combination with chemotherapy in the first line setting. This was the first overall survival data result from RILVE, and as AstraZeneca highlights in their ASCO investor call, the 16.8 months of overall survival was a clear example of prolonged stabilization of responses seen with RILVE across clinical trials, and the profile continues to support RILVE combination potential. In comparison, Historical trials for first-line BTC showed overall survival duration of less than 13 months. The data showed encouraging efficacy together with manageable safety profile, both of which we view as promising signals in a setting of high animate needs, while recognizing that longer follow-up and randomized data from the ongoing phase three trial in this setting will ultimately be needed to validate these findings. As AstraZeneca continues to advance revigostomy, across its broad late-stage program, we believe this sustained investment reflects ongoing confidence in Rilke Kostami. As a reminder, AZ has previously guided that Rilke has a non-risk-adjusted peak-year revenue potential of over $5 billion, and you remain eligible for future milestones of $195 million and up to mid-single-digit territories tied to Rilke Kostami progress and success. Moving to GS0321, formerly known as COM503, our potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead. GS0321 represents a novel antibody approach to harness cytokine biology for the treatment of cancer, potentially overcoming the limitations of direct cytokine administration. The ongoing Phase I dose escalation trial continues to progress as planned. As a reminder, We have received $90 million so far from Gilead on this asset, and we are eligible to receive up to $768 million in additional milestones payments, plus single-digit to low double-digit tiered royalties. Now moving to our early pipeline, Fueled by Unigen, our AI machine learning powered computational discovery platform, which has been developed and refined for more than a decade to identify novel drug targets and biological pathways grounded in human disease biology. As we have said before, our focus is not on using AI to optimize known biology, but on uncovering innovative opportunities to activate the immune system against cancer. UNIGINE has already discovered the targets of COM701, COM902, NGS0321, and we remain committed to identifying and advancing the next generation of immuno-oncology innovation. With that, I will turn the call over to David to review the financials.